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Rationale– The ubiquitin-proteasome system (UPS) and the autophagic-lysosomal pathway (ALP) are 
pivotal to proteostasis. Targeting these pathways is emerging as an attractive strategy for treating cancer. 
However, a significant proportion of patients who receive a proteasome inhibitor-containing regime show 
cardiotoxicity. Moreover, UPS and ALP defects are implicated in cardiac pathogenesis. Hence, a better 
understanding of the cross-talk between the two catabolic pathways will help advance cardiac 
pathophysiology and medicine.  
Objective– Systemic proteasome inhibition (PSMI) was shown to increase p62/SQSTM1 expression and 
induce myocardial macroautophagy. Here we investigate how proteasome malfunction activates cardiac 
ALP.  
Methods and Results– Myocardial macroautophagy, transcription factor EB (TFEB) expression and 
activity, and p62 expression were markedly increased in mice with either cardiomyocyte-restricted 
ablation of Psmc1 (an essential proteasome subunit gene) or pharmacological PSMI. In cultured 
cardiomyocytes, PSMI-induced increases in TFEB activation and p62 expression were blunted by 
pharmacological and genetic calcineurin inhibition and by siRNA-mediated Molcn1 silencing. PSMI 
induced remarkable increases in myocardial autophagic flux in wild type (WT) mice but not p62 null 
(p62-KO) mice. Bortezomib-induced left ventricular wall thickening and diastolic malfunction was 
exacerbated by p62 deficiency. In cultured cardiomyocytes from WT mice but not p62-KO mice, PSMI 
induced increases in LC3-II flux and the lysosomal removal of ubiquitinated proteins. Myocardial TFEB 
activation by PSMI as reflected by TFEB nuclear localization and target gene expression was strikingly 
less in p62-KO mice compared with WT mice.      
Conclusions– (1) The activation of cardiac macroautophagy by proteasomal malfunction is mediated by 
the Mocln1-calcineurin-TFEB-p62 pathway; (2) p62 unexpectedly exerts a feed-forward effect on TFEB 
activation by proteasome malfunction; and (3) targeting the Mcoln1-calcineurin-TFEB-p62 pathway may 
provide new means to intervene cardiac ALP activation during proteasome malfunction.   












Non-standard Abbreviations and Acronyms  
ALP  autophagic-lysosomal pathway 
BFA  bafilomycin A1  
CLEAR  the coordinated lysosomal expression and regulation element 
CnAβ  calcineurin catalytic subunit Aβ 
CsA  cyclosporine A  
CTL  control 
KO  knock out  
mTORC1 mechanistic target of rapamycin complex 1 
PFI  proteasome functional insufficiency 
Psmc1-cKO cardiomyocyte-restricted knockout of the Psmc1 gene 
PSMI  proteasome inhibition 
UPS  ubiquitin-proteasome system 






The ubiquitin-proteasome system (UPS) is responsible for the degradation of the vast majority of cellular 
proteins, pivotal to both protein quality control and the regulatory degradation of normal proteins 
essential to virtually all cellular processes.1 The autophagic-lysosomal pathway (ALP) also plays a crucial 
role in intracellular quality control via removal of aberrant protein aggregates and defective or surplus 
organelles, in addition to provision of fuels by self-digesting a portion of cytoplasm during energy crisis.2 
UPS and ALP were historically believed to function in parallel in the cell but emerging evidence suggests 
their cross-talk although the underlying molecular mechanisms remain poorly understood.3  
In UPS-mediated protein degradation, the proteasome carries out the final proteolytic step of 
poly-ubiquitinated proteins and, as indicated by emerging evidence, its functioning is highly regulated 
and often constitutes the rate–limiting step.4 Studies on human myocardium with cardiomyopathies and 
end-stage heart failure have yielded compelling evidence that cardiac proteasome functional insufficiency 
(PFI) occurs in a large subset of heart disease during progression to heart failure and may play a major 
pathogenic role therein.5, 6 Studies using animal models have established the necessity of PFI in both rare 
and common forms of cardiac disorders such as cardiac proteinopathy,7 myocardial ischemia/reperfusion 
injury,7-9 pressure-overloaded cardiac hypertrophy and failure,10, 11 and diabetic cardiomyopathy.12 
Therefore, beyond search for measures to improve cardiac proteasome functioning,13 a better 
understanding of how cardiomyocytes and hearts respond to proteasome impairment will help identify 
potential therapeutic strategies to maintain cardiac proteostasis. Prior studies have shown that 
pharmacological proteasome inhibition (PSMI) increases myocardial macroautophagy (hereafter referred 
to as autophagy);14 and both autophagy and p62/SQSTM1 in cardiomyocytes are markedly increased in 
the compensatory stage of cardiac proteinopathy.15, 16 The latter exemplifies heart disease with increased 
proteotoxic stress and is associated with PFI.15-18 However, the molecular mechanisms governing the 
activation of autophagy by proteasome malfunction and the role of p62 upregulation in the induction of 
cardiac autophagy by PSMI remain undefined.  
Transcription factor EB (TFEB) is a master regulator of lysosomal genesis, ALP, and catabolism. 
At baseline, TFEB is phosphorylated at multiple residues by kinases including the all-important 
mechanistic target of rapamycin complex 1 (mTORC1) and possibly extracellular signal-regulated kinase 
2 and MAP4K3.19 Phosphorylated TFEB is bound by chaperone 14-3-3 and segregated in the cytoplasm 
where a large fraction of, if not all, TFEB proteins are localized on the membrane of lysosomes. During 
starvation or lysosomal stress, mTORC1 is inactivated and stops phosphorylating TFEB while TFEB is 
dephosphorylated by calcineurin, allowing TFEB nuclear translocation. Here the activation of calcineurin 




TFEB binds to a common 10-base E box-like palindromic sequence, referred to as the coordinated 
lysosomal expression and regulation (CLEAR) element, and thereby activates the transcription of an 
entire network of genes harboring the CLEAR motif. This network is known as the CLEAR network 
consisting of genes involved in lysosomal genesis, autophagosome formation and even mitochondrial 
biogenesis.21 The role of TFEB activation in cardiac pathophysiology has begun to unveil;16, 22-25 however, 
it remains untested how TFEB participates in the crosstalk between the UPS and ALP, especially in 
bridging proteasome malfunction and autophagy activation. Hence, we performed the present study to 
address these critical questions.  
The present study has identified that both TFEB activation and p62/Sqstm1 upregulation were 
induced by both genetic and pharmacological PSMI in the heart and cardiomyocytes, established that 
TFEB activation by PSMI is calcineurin- and Mcoln1- dependent, demonstrated that p62 is required for 
induction of autophagy by PSMI and for lysosomal removal of ubiquitinated proteins in cardiomyocytes 
with proteasome malfunction, and discovered that p62 exerts an unexpected feedforward effect on the 
TFEB activation by PSMI. Taken together, the present study identifies the Mcolon1-calcineurin-TFEB-
p62 pathway for proteasome malfunction to induce autophagy in the heart, which yields new mechanistic 
insight into the crosstalk between the UPS and ALP and provides potentially new therapeutic targets for 
modulating cardiac proteostasis.    
         
MATERIALS AND METHODS 
(A full description of Materials and Methods can be found in online supplements.)  
The authors declare that all supporting data are available within the article and its online supplementary 
files. 
Animal models.  
The mice harboring the Psmc1 floxed allele (Psmc1f/f),26 the αMyHC-Cre transgenic (tg) mouse  
[B6.FVB-Tg(Myh6-cre)2182Mds/J; also known as αMyHC-Cre],27 global p62 knockout (p62-KO) 
mice,28 GFPdgn tg mice,29 and the GFP-LC3 tg mice,30 were previously described. All mice were 
converted to C57BL/6J background before being used for this current study. All protocols for animal use 
and care were approved by the University of South Dakota Institutional Animal Care and Use of 
Committee and conform to the NIH Guide for the Care and Use of Laboratory Animals.  




These were done as reported.15, 23  
Statistical methods  
GraphPad Prism software (Version 8.4.1; GraphPad Software, San Diego, CA 92108) was used. All 
continuous variables are presented as mean ± SD unless indicated otherwise. All data were examined for 
normality with the Shaprio Wilk’s test prior to application of parametric statistical tests. Those that failed 
this test were analyzed with the Mann-Whitney test. Tests used for statistical significance evaluations of 
each data set are specified in figure legends. In all cases where 1-, 2-, or 3-way ANOVA was used, there 
was a significant overall treatment effect and Tukey's test was performed for pairwise comparisons. A p 
value <0.05 is considered statistically significant, which yielded a False Discovery Rate (FDR) below 5% 
for any of the multiple testing in this study (Figures 5E, 6C, 6F, and 8B) as estimated with the Benjamini 
Hochberg method. The Holm-Sidak method was used for multiple testing correction whenever multiple t 
tests were used.   
 
RESULTS  
1. Increases in myocardial p62, LC3-II, and autophagosomes in Psmc1CKO mice 
To date, the impact of cardiac proteasome malfunction on autophagy has not been examined in a 
genetic model of PSMI. PSMC1/Rpt2 is an AAA-ATPase subunit of the 19S proteasome and is required 
for the assembly and functioning of 26S proteasomes.26, 31 Using the Cre-Loxp system, we achieved 
perinatal cardiomyocyte-restricted knockout of the Psmc1 gene (Psmc1CKO; Supplementary Figure Ⅰ). 
Comparing the homozygous Psmc1CKO (αMyHC-Cre+::Psmc1f/f) mice with littermate control mice (CTL) 
consisting of αMyHC-Cre+, Psmc1f/+, Psmc1f/f, and heterozygous Psmc1CKO (αMyHC-Cre+::PSMC1f/+) 
mice, we confirmed the deletion of the Psmc1 gene in cardiomyocytes, resulting in ~85% reduction of 
myocardial Psmc1 proteins and the loss of nuclear-enriched Psmc1 staining in cardiomyocytes, but not in 
non-cardiomyocyte cells (Supplementary Figure ⅠB-D). As expected,26 Psmc1CKO caused substantial 
accumulation of myocardial ubiquitinated proteins and, when coupled with a UPS surrogate substrate 
GFPdgn,29 increased  myocardial GFPdgn protein levels (Figure 1A-1C). Thus, we have created a genetic 
model of cardiomyocyte-restricted PSMI.  
We then probed the impact of genetic PSMI on the ALP.  Loss of Psmc1 led to ~1.6-fold 
upregulation of myocardial LC3-II (an autophagosome marker) and ~3.3-fold of increase in p62/Sqstm1, 




ubiquitinated proteins to autophagosomes for degradation.32 We found the increased p62 frequently co-
localized with ubiquitin-positive aggregates in Psmc1CKO hearts (Figure 1D). To visualize the abundance 
of autophagosomes, we cross-bred a GFP-LC3 transgene into CTL and Psmc1CKO mice and observed 
more than 5-fold increases of GFP-positive puncta in Psmc1CKO hearts (Figure 1G-1H). Together, these 
in vivo data suggest that genetic PSMI induces the ALP in the heart.  
Homozygous Psmc1CKO mice developed severe cardiac failure shortly after birth, as revealed by 
conscious echocardiography (Echo) at postnatal day 2. Echo analyses showed unchanged left ventricular 
(LV) end-diastolic posterior wall thickness (LVPW) but increased LV internal diameter (LVID) at both 
end-diastole and end-systole, decreased LV ejection fraction (EF), and reduced conscious heart rate in 
comparison with their littermate controls, including αMyHC-Cre transgenic, Psmc1f/+, Psmc1f/f, and 
heterozygous Psmc1CKO mice. All homozygous Psmc1CKO mice died by postnatal day 10 (Supplementary 
Figure Ⅱ). Our data demonstrate that Psmc1 is essential for cardiac UPS function, cardiac development 
and perinatal survival in mice.  
2. Upregulation of p62 and autophagic flux in cardiomyocytes by genetic PSMI  
The increase of autophagosomes observed in Psmc1CKO hearts could be secondary to cardiac 
dysfunction and/or a consequence to an impairment in the removal of autophagosomes. To address this 
question, we tried autophagic flux assays using intraperitoneal injections of bafilomycin A1 (BFA) to 
block lysosomal removal of autophagosomes but our multiple attempts failed because, unlike 2-week-old 
or older mice,33 the BFA-treated neonatal mice (5 days or younger), especially the Psmc1CKO ones, died 
before a discernible cardiac lysosome inhibition can be achieved. Hence, we turned to cardiomyocyte 
cultures for autophagic flux assays. First, we induced Psmc1 deletion by infecting neonatal 
cardiomyocytes from Psmc1f/f mice with adenoviruses expressing Cre (Ad-Cre). LC3-II proteins were 
significantly reduced in Psmc1-depleted cells, and inhibition of lysosomes with bafilomycin A1 (BFA) 
led to a greater increase of LC3-II in these cells when compared with the control cells (Figure 2A, C, D); 
by contrast, Ad-Cre did not alter LC3-II flux in WT mouse cardiomyocytes (Figure 2B-D). These data 
demonstrate that PSMI via ablation of Psmc1 increases LC3-II flux in cardiomyocytes. Next, we silenced 
Psmc1 in neonatal rat ventricular myocytes (NRVMs) using Psmc1-speicfic siRNA (siPsmc1), which led 
to a remarkable increase in total ubiquitinated proteins and p62 (Figure 2E, F). Lysosomal inhibition 
with BFA accumulated more p62 proteins in NRVMs transfected with siPsmc1 than in those treated with 
a control siRNA targeting Luciferase (siLuci) (Figure 2G-I), indicating that Psmc1 knockdown increases 
p62 flux, another indicator of autophagic flux.34 The LC3-II flux or p62 flux index (Figure 2D, 2I) 




lysosomal inhibition. Consistently, confocal microscopy of double-immunostaining for LC3 and ubiquitin 
detected that siPsmc1 increased both ubiquitin and LC3 puncta in cultured NRVMs and that BFA 
treatment appeared to accumulate more LC3 puncta and ubiquitin puncta in siPsmc1 treated NRVMs than 
in those treated by siLuci (Figure 2J), which further supports that genetic PMSI increases autophagic flux 
in cardiomyocytes. Notably, most of the LC3 puncta are ubiquitin-positive (Figure 2J), suggesting that 
removal of the ubiquitinated proteins accumulated by PSMI is a major role of the increased autophagic 
flux. Together, these data demonstrate compellingly that genetic PSMI is sufficient to activate autophagy 
in cardiomyocytes.  
3. Activation of myocardial TFEB in mice by pharmacological and genetic PSMI  
 The molecular mechanisms underlying the interplay between the UPS and autophagy are 
incompletely understood. TFEB is a master regulator of autophagy and lysosome function by acting as a 
transcription factor that induces the expression of a network of genes involved in autophagosome and 
lysosome biogenesis.19 Western blot analysis showed that administration of a bolus of bortezomib (BZM, 
10 µg/kg), markedly increased myocardial p62 (Figure 3A, B) and ubiquitinated proteins in mice 
(Supplementary Figure Ⅲ). This was accompanied by a reduction of the slower-migrating TFEBa band 
and consequently an increase of its faster migrating counterpart (Figure 3A), indicative of increases in 
dephosphorylated TFEBa by pharmacological PSMI. Dephosphorylated TFEB is prone to nuclear 
translocation to induce autophagy.19 Indeed, subcellular fractionation analyses revealed increases of 
TFEBa in both cytoplasmic and nuclear fractions of the myocardium from mice treated with BZM, 
compared with vehicle control treatment (Figure 3C ~ 3E; Supplementary Figure Ⅳ). Similarly, PSMI 
seemed to have triggered nuclear translocation of TFEBb as well (Figure 3C). In further support of the 
transactivation of TFEB by PSMI, gene expression analyses revealed significant increases in the mRNA 
levels of Uvrag, Vps18, Mcoln1, M6PR and p62/Sqstm1, the well-known target genes of TFEB,19 in 
BZM-treated mouse hearts (Figure 3F, G).  
 To determine if genetic PSMI also activates TFEB, we performed immunostaining to analyze TFEB 
localization in mouse hearts at postnatal day 2 and observed ~3-fold more cardiomyocytes with nuclear 
TFEB-positive staining in Psmc1CKO hearts (Figure 4A, 4B). Western blot analysis revealed that 
depletion of Psmc1 resulted in a significant increase of TFEBa proteins in mouse hearts (Figure 4C-4D). 
Psmc1CKO also significantly increased the transcripts of TFEB target genes including p62/Sqstm1, Uvrag, 
Vps18 and Mcoln1 (Figure 4E).  
 In cultured NRVMs, BZM treatment also dramatically reduced the slower-migrating TFEBa and 
increased the faster-migrating TFEBa (Figure 5A), indicative of enhanced dephosphorylation and nuclear 
translocation. Indeed, subcellular fractionation analyses showed that nuclear TFEBa is the faster-




and 24 hours (Figure 5B, C). Immunostaining for TFEB further confirmed that more BZM-treated 
cardiomyocytes than the control cells displayed nuclear enrichment of TFEB (Figure 5D). The mediating 
role of TFEB in the induction of p62 and other ALP genes by PSMI was further confirmed by the TFEB 
knockdown experiments, which revealed that TFEB knockdown significantly attenuated PSMI-induced 
upregulation of the mRNA levels of p62 and other ALP-related genes (Figure 5E) and p62 proteins 
(Supplementary Figure Ⅴ).  
Together, these lines of in vivo and in vitro evidence compellingly demonstrate that both 
pharmacological and genetic PSMI activate TFEB and its downstream signaling in cardiomyocytes.  
4. TFEB activation by PSMI in a calcineurin-dependent manner  
Phosphorylation of TFEB dictates its subcellular localization and transcriptional activity; the 
dephosphorylated TFEB translocates from cytoplasm to the nucleus where it initiates downstream gene 
expression.19 We have previously reported that PSMI activates the calcineurin-NFAT pathway in 
cardiomyocytes and mouse hearts.35 Here we observed that the mRNA levels of MCIP1.4, a target gene of 
the calcineurin-NFAT pathway, were significantly higher in cultured NRVMs and mouse hearts that were 
treated with a proteasome inhibitor than those in the controls (Supplementary Figure Ⅵ). Cyclosporine 
A (CsA) is a potent calcineurin inhibitor. CsA treatment restored the levels of the slower-migrating TFEB 
bands in the BZM-treated cardiomyocytes in a dose-dependent manner (Supplementary Figure Ⅶ), 
indicating that calcineurin activation is responsible for PSMI-induced TFEB dephosphorylation. 
Subcellular fractionation (Figure 6A, B) and immunostaining (Supplementary Figure Ⅷ) further 
confirmed that inhibition of calcineurin by CsA blunted BZM-induced TFEB nuclear translocation. 
Moreover, CsA treatment attenuated BZM induction of an array of TFEB target genes involved in 
autophagy and lysosome biogenesis (Supplementary Figure ⅨA, B). Genetic inhibition of calcineurin 
via calcineurin Aβ knockdown also significantly attenuated the activation of TFEB target genes by PSMI 
(Figure 6C). Together, these findings demonstrate that calcineurin activity is required for PSMI to 
activate TFEB in cardiomyocytes.  
5. TFEB activation by PSMI requires Mucolipin 1 (Mcoln1)  
Mcoln1, also known as transient receptor potential mucolipin 1 (TRPML1), is the main calcium 
channel on the membrane of late endosomes and lysosomes.20 It is purported that during autophagic 
activation, calcium released from lysosomes via Mcoln1 activates calcineurin, which in turn 
dephosphorylates TFEB and promotes TFEB nuclear translocation.20 To our best knowledge, this has not 




in BZM-treated hearts, Psmc1CKO hearts, and BZM-treated cultured cardiomyocytes (Figures 3, 4, 6). We 
then determined the impact of silencing Mcoln1 via transfection of Mcoln1-specific siRNA on PSMI-
induced TFEB activation in cultured NRVMs. Our results showed that silence of Mcoln1 effectively 
suppressed BZM-induced TFEB nuclear translocation (Figure 6D, E) and attenuated BZM-induced 
upregulation of TFEB downstream genes (Figure 6F, Supplementary Figure ⅨC, D). Thus, we 
conclude that PSMI-induced TFEB activation requires Mcoln1.  
6. Requirement of p62 for PSMI to increase autophagy flux in mouse cardiomyocytes and hearts  
p62 can serve as an adaptor protein that bridges ubiquitinated proteins or organelles to 
autophagosomes for selective degradation although p62 also may play a role in non-selective autophagy 
and even non-autophagy processes.32 This is supported by the co-localization among p62, ubiquitin, and 
LC3 puncta in cardiomyocytes with PSMI (Supplementary Figure Ⅹ). PSMI upregulates p62 at both 
mRNA and protein levels in the heart (Figures 1E, 2A, 3A, 3B, 3F, 3G and 4E) in a TFEB dependent 
manner (Supplementary Figure Ⅴ) but its roles in PSMI-induced autophagy and TFEB activation are 
not clear. At baseline, myocardial LC3-II flux was comparable between wild type (WT) and p62-KO 
mice; PSMI with MG-262 significantly increased LC3-II turnover in WT mouse hearts but not in p62-KO 
hearts (Figure 7A~7C). To determine whether the effect of p62-KO observed in mouse hearts is 
cardiomyocyte-autonomous, we also performed similar tests in cultured mouse cardiomyocytes isolated 
from WT and p62-KO neonatal mice. Similar to the results from the in vivo tests, PSMI induced a 
significant increase in LC3-II flux in WT cardiomyocytes but not in p62-KO cardiomyocytes. Different 
from the in vivo findings, LC3-II flux was significantly lower in p62-null cardiomyocytes than in WT 
cardiomyocytes under the basal condition (Figure 7D~7F). Moreover, we also assessed the effects of 
PSMI with BZM and of lysosome inhibition with BFA on the level of steady state ubiquitin conjugates in 
these cardiomyocytes (Supplementary Figures Ⅺ). Treatment with either BZM or BFA alone induced a 
marked increase of total ubiquitinated proteins in both WT and p62-KO cells but the increase in the p62-
KO cells was much less than in the WT cells. The treatment combining BZM and BFA showed a 
discernible additive effect in the WT but not p62-KO cells, indicating that p62 is required for proteasome 
malfunction to increase the lysosome-mediated clearance of ubiquitinated proteins in cardiomyocytes. 
Importantly, experiments using cultured NRVMs also revealed that genetic PSMI via siRNA-mediated 
Psmc1 silence induced remarkably less accumulation of total ubiquitinated proteins in the cells with 
siRNA-mediated p62 depletion compared with those without p62 depletion (Supplementary Figures 
Ⅻ). Taken together, these in vivo and in vitro experiments demonstrate that compensatory upregulation 
of autophagic degradation of ubiquitinated proteins under a PSMI or proteasome malfunction state 





7. p62 deficiency exacerbates PSMI-induced LV diastolic malfunction  
At baseline, 5~6 weeks old p62-KO mice showed a moderate decrease in the body weight (BW)-
normalized Echo-derived LV mass and corrected LV mass, compared with WT mice (p=0.028 for both) 
but the BW and all other Echo-based parameters were comparable between them (Supplementary Table-
S1). We treated sex-matched WT and p62-KO mice with daily intraperitoneal injections of BZM (1mg/g) 
or vehicle control. We observed no difference in mouse mortality as each group had a BZM-treated 
mouse died at the third and fourth days after initiation of the injection. We performed longitudinal 
comparison of Echo parameters within each mouse between 3 hours post the 3rd injection and baseline 
(Supplementary Figures ⅩⅢ and ⅩⅥ). The 3 consecutive daily injections of BZM did not consistently 
change the heart rate in either genotype but led to significant BW decreases and the decreases are 
comparable between two genotypes. BZM-induced increases in EF and fractional shortening (FS), as well 
as changes in all other end-systolic parameters are not significantly different between WT and p62-KO 
mice. However, the BZM-induced increases in all end-diastolic parameters as well as the decreases in LV 
end-diastolic volume/BW, stroke volume (SV), cardiac output (CO), SV/BW, and CO/BW are 
significantly greater in p62-KO mice than in WT mice. Echo-based LV mass and corrected LV mass were 
significantly decreased by BZM in WT but not p62KO mice and a similar trend was evident when the LV 
mass parameters were normalized to BW.  Hence, the moderate difference of the BW-normalized LV 
mass parameters between the two genotypes at baseline was obliterated by BZM treatment, resulting in a 
comparable heart weight/BW ratio or ventricular weight/BW ratio between the two genotypes after the 
BZM treatment (Supplementary Figure ⅩⅤ). Taken together, these data indicate that p62 protects 
against PSMI from impairing diastolic function. 
    
8. A positive feedback by p62/Sqstm1 on TFEB activation  
p62 is a TFEB target gene. Our data presented thus far also compellingly support that induction of 
p62 by PSMI in cardiomyocytes is mediated by TFEB activation. Although p62 is just one of the TFEB 
target genes, PSMI-induced increases in autophagic removal of both LC3-II and ubiquitinated proteins 
were completely abolished in mouse hearts and cardiomyocytes deficient of p62. This prompted us to 
speculate that p62 is required for PSMI to sustain TFEB activation; hence, we further compared the TFEB 
activation by PSMI between WT and p62-KO mice. Immunofluorescence confocal microscopy showed 
that p62 deficiency significantly attenuated PSMI-induced TFEB nuclear translocation (Figure 8A). 
mRNA expression analyses further showed that induction of representative TFEB target genes by PSMI 
was discernibly less effective in p62-KO mice than in WT mice (Figure 8B, Supplementary Figure 




activation during PSMI. To explore preliminarily a potential underlying mechanism, we found that BZM 
treatment suppressed mTORC1 and mTOR proteins largely co-localized with the increased p62 puncta in 
NRVMs treated with BZM (Supplementary Figure-ⅩⅦ).  
 
DISCUSSION   
Both UPS and ALP are pivotal to protein quality and quantity control in the cell. Targeting these 
pathways is becoming an attractive strategy for treating human disease, especially for cancer therapies. 
For example, proteasome inhibitors are highly efficacious in treating multiple myeloma.36 However, a 
significant proportion of patients receiving a proteasome inhibitor-containing regime show 
cardiotoxicity.37 Moreover, UPS and ALP defects are implicated in the pathogenesis of a large subset of 
heart disease or heart failure.2 Therefore, a better understanding of the interplay between these two 
catabolic pathways is expected to advance cardiac pathophysiology and to identify potentially new 
therapeutic targets. Prior studies have suggested that proteasome malfunction increases p62 and activates 
autophagy in cardiomyocytes but the underlying mechanisms were unclear.14, 15 Here we have confirmed 
this with genetically induced cardiac PSMI. More importantly, we have delineated for the first time the 
Mcoln1-calcineurin-TFEB-p62 pathway in mediating the autophagic activation by proteasome 
malfunction and discovered that Mcoln1 and p62 play an essential feed-forward role in TFEB activation 
by PSMI (Figure 8C). Activation of autophagy apparently acts to minimize the toxicity resulting from 
proteasome malfunction and thereby helps maintain proteostasis in the cell. These discoveries provide 
significant mechanistic insight into cardiac proteostasis.  
1. Proteasome malfunction activates the ALP  
Both proteasome malfunction and activation of autophagy are observed in the heart of well-
established mouse models of cardiac proteinopathy and a mouse model of hypertrophic cardiomyopathy 
that carries a mutant of myosin-binding protein C.15, 38 Supporting a functional link between the UPS and 
the ALP in myocardium, administration of BZM to mice increased autophagosomes and autophagic flux 
in the heart.14 The present study has achieved and characterized cardiomyocyte-restricted ablation of an 
essential proteasome subunit gene (Psmc1) for the first time in vertebrates (Supplementary Figure Ⅰ, Ⅱ), 
which along with genetic PSMI in cultured cardiomyocytes confirms that PSMI activates autophagy 
(Figure 1 and 2). PSMC1 is indispensable for 26S proteasomes. Deletion of Psmc1 in neurons caused 
neuronal degeneration in mice.26 Here we report that targeting Psmc1 in mouse hearts also led to severe 
proteasome impairment, as evidenced by the drastic accumulation of ubiquitinated proteins and protein 
aggregates and by a significant increase of the proteasome surrogate substrate (GFPdgn). Upon 




autophagic proteins, including p62 and LC3-II in the heart. Moreover, p62 frequently co-localized with 
ubiquitinated proteins and LC3 puncta (i.e., autophagosomes) in Psmc1-depleted cardiomyocytes 
(Supplementary Figure Ⅹ), representing an intermediate state of these cargos en route to lysosomal 
degradation. These lines of evidence, coupled with the increased autophagic flux in Psmc1-deficient 
cardiomyocytes, demonstrate that autophagy is activated by genetically induced proteasome malfunction 
in the heart. Apparently, the ALP activation is not sufficient to compensate loss of proteasome function in 
the heart because perinatal Psmc1 ablation in cardiomyocytes resulted in severe dilated cardiomyopathy 
and mouse premature death (Supplementary Figure Ⅱ).  
2. Proteasome malfunction activates TFEB 
One of the most important contributions of this study is the discovery that PSMI activates TFEB, the 
master transcription regulator for the ALP. First, we found that pharmacological PSMI increases 
myocardial TFEB protein levels, TFEB nuclear translocation, and TFEB target gene expression (Figure 
3); second, genetic PSMI via Psmc1CKO increased TFEB nuclear localization and TFEB target gene 
expression in mice (Figure 4); and lastly, PSMI induced rapidly TFEB dephosphorylation, nuclear 
translocation, target gene expression in a cardiomyocyte-autologous manner (Figures 5, 6). Thus, both in 
vitro and in vivo evidence compellingly demonstrate a rapid activation of TFEB by proteasome 
malfunction.  
 The activation of TFEB is capable of upregulating coordinately the full spectrum of ALP genes 
required for sustained autophagic degradation. Indeed, induction of ALP genes including p62 by PSMI in 
cardiomyocytes was significantly attenuated by TFEB inhibition (Figure 5E and Supplementary Figure 
Ⅴ). Hence, our identification of a previously unrecognized role of TFEB in mediating the crosstalk 
between the UPS and ALP is highly significant because increasing TFEB has been shown to confer 
cardioprotection under a number of pathological conditions.22, 23, 39  
3. Proteasome malfunction activates TFEB via Mcoln1-Calcineurin  
In TFEB activation by starvation, calcineurin which is activated by the calcium released from the 
lysosome via Mcoln1, is responsible for the dephosphorylation of TFEB.20 The role of calcineurin in the 
activation of TFEB by PSMI has not been examined in any cell types before. We previously showed the 
activation of the calcineurin-NFAT pathway in cultured cardiomyocytes by PSMI and in the heart of mice 
with UPS functional insufficiency.35 And this is further confirmed in the present study because the mRNA 
levels of MCIP1.4/Rcan1, a bona fide target gene of the calcineurin-NFAT pathway, were significantly 
increased by PSMI in both cultured cardiomyocytes and intact mice (Supplementary Figure Ⅵ). This 




inhibition of calcineurin phosphatase activity with CsA diminished PSMI-induced TFEBa 
dephosphorylation in a dose-dependent fashion (Supplementary Figure Ⅶ) and markedly reduced 
PSMI-induced TFEB nuclear localization and target gene expression (Figure 6; Supplementary Figure 
Ⅷ). This is further supported by that siRNA-mediated calcineurin inhibition also significantly 
attenuated the induction of representative TFEB target genes by PSMI (Supplementary Figure Ⅸ).   
The role of Mcoln1 in TFEB activation was not investigated previously in cardiomyocytes; moreover, 
the role of Mcoln1 in the activation of TFEB by PSMI has not been examined in any cell types before. 
Here we found that as a target gene of TFEB, Mcoln1 expression was significantly increased by PSMI 
whereas prevention of this increase  abolished PSMI-induced TFEBa nuclear translocation and the 
expression of TFEB target genes (Figure 6), demonstrating for the first time that Mcoln1 is indispensable 
in the TFEB activation by PSMI. This also indicates that calcium release from lysosomes to the cytosol 
via Mcoln1 plays an essential role in the activation of the phosphatase calcineurin by PSMI and that 
Mcoln1 exerts a feedforward role in the TFEB activation by PSMI. Since it has been reported that 
calcineurin is degraded by the UPS and calcineurin proteins accumulate in mouse hearts with UPS 
impairment,35, 40 it is highly likely that PSMI increases calcineurin activities through both stabilization of 
calcineurin proteins and, via Mcoln1, facilitation of calcineurin activation. As a lysosomal calcium 
channel, Mcoln1 can be activated by lysosomal stress.41 Upon PSMI, the share of ubiquitinated proteins 
that goes to the ALP for degradation is dramatically increased and thereby imposes stress on lysosomes. 
Mcoln1 can act as a reactive oxygen species (ROS) sensor and be activated by increased ROS;42 hence, 
the activation of Mcoln1 by PSMI may also be through increasing ROS as PSMI has been shown to 
increase ROS production in the cell.43   
4. The role of p62/Sqstm1 in the activation of autophagy by PSMI  
We previously reported upregulation of myocardial p62 and autophagy in mouse models of cardiac 
proteinopathy.15 Here we collected both in vivo and in vitro evidence that both pharmacological and 
genetic PSMI upregulate both mRNA and protein levels of p62 in cardiomyocytes (Figures 1~4, 6, 7). At 
least a part of this upregulation is mediated by TFEB because inhibition of TFEB activation via 
calcineurin inhibition, Mcoln1 knockdown (Figure 6), or TFEB knockdown (Supplementary Figure Ⅴ) 
all blunted the induction of p62 by PSMI. In agreement with our findings, a recent study detected in non-
cardiac cells that a short exposure to BZM could lead to a rapid increase in the mRNA levels of p62 and 
GABARAPL1 but not in other ALP genes although a longer exposure induced most of them.44 In stark 
contrast to our findings, their further experiments showed TFEB knockdown did not alter the induction of 
p62 by BZM in M17 cells,44 suggesting the mechanisms by which PSMI upregulates p62 may be cell-




p62 can bind ubiquitinated substrates via its ubiquitin-associated domain (UBA) and help the bound 
cargos to form aggregates through its PB1-domain-mediated self-oligomerization;3 meanwhile, p62 
recruits and activates the core autophagosome machinery and recruits ATG8/LC3 decorated phagophore 
via its LC3-interacting region (LIR).32, 45 Hence, p62 acting as the prototype receptor for ubiquitinated 
cargos plays likely an important role in cargo-initiated selective autophagy. However, the in vivo 
necessity of p62 in cardiac proteostasis at baseline and during proteotoxic stress was not established 
before the present study. Here we detected that the basal level of myocardial lysosome-mediated LC3-II 
flux was comparable between WT and p62-KO mice but the responses of the LC3-II flux to PSMI were 
drastically different between them (Figure 7A~7C). During PSMI, myocardial LC3-II flux was 
substantially increased in WT mice but the flux became completely undetectable in the p62-KO mice. 
Similar findings were obtained in cultured neonatal mouse cardiomyocytes but, notably, p62-deifciency 
significantly decreased LC3-II flux and the lysosome-mediated flux of ubiquitinated proteins under both 
the control culturing condition and during PSMI (Figure 7D~7F, Supplementary Figure Ⅺ). This 
difference between in vivo and cell culture studies is likely caused by that cardiomyocytes when cultured 
in vitro experience inevitable stresses even in absence of exposure to a proteasome inhibitor. Taken 
together, these new in vivo and in vitro findings support compellingly that p62 is required for activation 
of autophagy and for lysosomal removal of ubiquitinated proteins in cardiomyocytes and hearts during 
proteasome malfunction.  
There is strong evidence that the rapid upregulation of p62 by PSMI helps channel ubiquitinated 
proteins to the ALP for degradation and thereby alleviates the accumulation of ubiquitinated proteins 
resulting from proteasome malfunction. p62 does so through promoting the aggregation of ubiquitinated 
proteins and targeting the ubiquitinated cargoes to the ALP. This is consistent with our findings that most 
p62 proteins are co-localized with ubiquitin-positive protein aggregates and LC3-positive puncta in 
cardiomyocytes with PSMI (Figures 1D, 2I and Supplementary Figure Ⅹ).   Besides binding to 
ubiquitinated cargos and targeting them selectively to the ALP, p62 was recently shown to recognize and 
bind the N-degron in proteins that are normally degraded by the UPS via the N-end rule pathway.46 
Hence, upon proteasome impairment, the accumulated proteins with an N-degron may use the 
upregulated p62 as the bridge to the ALP pathway in a ubiquitin-independent manner. Nevertheless, the 
rapid upregulation of p62 by PSMI requires ubiquitination, according to a recent report.44 Consistent with 
findings from prior studies using cultured cells,44 including cultured cardiomyocytes,15 our in vivo and in 
vitro work revealed that the PSMI-induced increases in the steady state total ubiquitinated proteins in 
hearts (data not shown) and cultured cardiomyocytes (Supplementary Figures Ⅺ) were significantly 
less in p62-KO mice compared with WT mice and this was recapitulated in NRVMs subjected to siRNA-




of p62-meidated aggregation, a significant portion of ubiquitinated proteins may undergo deubiquitination 
in cardiomyocytes with proteasome malfunction.  
5. The role of p62/Sqstm1 in the activation of TFEB by PSMI  
An unexpected finding of this study is that p62 positively feeds back on TFEB activation in the heart, 
as evidenced by that cardiac TFEB nuclear localization and target gene expression induced by PSMI were 
remarkably attenuated in the p62-KO mice than the WT mice (Figure 8). The mechanism by which p62 
does so is currently unclear. Nevertheless, we detected that PSMI suppressed mTORC1 activities 
(Supplementary Figure ⅦA, B), which is consistent with TFEB activation by PSMI because mTORC1 
phosphorylates and inactivates TFEB.19 More interestingly, an increased proportion of mTOR proteins 
was co-localized with p62-positive protein aggregates in BZM-treated NRVMs (Supplementary Figure 
ⅩⅦC). Hence, we propose that p62-meidated aggregation of ubiquitinated proteins during PSMI 
sequesters mTOR and prevents it from phosphorylating TFEB, rendering TFEB more susceptible to 
calcineurin-mediated dephosphorylation. It is also conceivable that the consumption of lysosomal 
machinery by p62-mediated increases of autophagy during PSMI can activate TFEB to replenish ALP 
machinery.   
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 increased myocardial p62, LC3-II, and autophagosomes in mice. A, Western 
blot analyses for the indicated proteins in the hearts of CTL (yellow circle; n=5) and Psmc1CKO (red 
circle; n=6) mice at postnatal day 2 (P2). Ub, ubiquitin conjugates. B and C, GFPdgn transgene was 
introduced into CTL (n=3) and Psmc1CKO (n=5) mice. Myocardial GFPdgn protein levels in indicated P2 
mice were assessed by western blot (B) and quantified (C). D, Immunostaining of ubiquitin (green) and 
p62 (red) in myocardium sections from P2 mice. Arrowheads mark cardiomyocytes with increased 
ubiquitinated proteins and p62. Nuclei were counter-stained with DAPI (blue). Bar, 10 µm. E and F, 
Western blots (E) of myocardial LC3 (n=4 mice for CTL and 3 for Psmc1CKO) and p62 (n=4 mice for 
CTL and 4 for Psmc1CKO) at P2 and the quantification (F). G and H, GFP-LC3 transgene was crossed into 
CTL and Psmc1CKO (KO)  mice to label autophagosome (green puncta). Shown are confocal fluorescent 
images (G) of myocardium sections from P2 mice and the quantification of GFP-positive puncta (H) 
where 4 CTL and 3 KO mice were used and 2 technical repeats per mouse were included. Bar, 10 µm. 
The precise p values are shown immediately above the pairwise comparison bracket (the same for all 
figures) and they are from two-sided and unpaired t test (C, F), or nested t-tests (H).  
 
Figure 2. Genetic inhibition of the proteasome increases p62 and autophagic flux in 
cardiomyocytes. A - D, Neonatal mouse ventricular cardiomyocytes (NMVMs) were isolated from 
neonatal PSMC1f/f (A) or WT (B) mice and infected with Ad-Gal (circle) or Ad-Cre (triangle) for 72 
hours. The cells were treated with vehicle (Veh) or Bafilomycin A1 (BFA, 100 nM) for 4 hours before 
harvest. Shown are representative western blots of the indicated proteins (A, B) and the pooled 
densitometry data of LC3-II (C) and derived LC3-II flux (D).  E - J, Neonatal rat ventricular myocytes 
(NRVMs) were transfected with siRNAs targeting Psmc1 (siPSMC1; red) or luciferase (siLuci, yellow) 
for 72 hours. Some of the cells were treated with BFA (100 nM, 2 hours) or Veh for autophagic flux 
assays (G-J).  E-I, Western blots (E, G) and the quantification of p62 (H) and the derived p62 flux (I). 
Each lane and dot represent a biological repeat; n=4 biological repeats for each group in all quantitative 
panels. The p values shown are either the precise p values derived from two-sided and unpaired t test (D, 
I) or the adjusted p values from two way ANOVA followed by Tukey’s tests (C, H) or from multiple t-
tests corrected for multiple testing with the Holm-Sidak method (F). J, Representative confocal 
fluorescent images of cells immunostained for ubiquitin (Ub, green) and LC3 (red).      
Figure 3. Pharmacological PSMI increases myocardial p62 and activates TFEB in mice. Mixed sex 




control (60% DMSO in saline; solid circle) for 12 hours. Ventricular myocardium was sampled for 
protein and RNA analyses. A and B, Western blots (A) of indicated proteins and pooled densitometry data 
of p62 proteins (B). N= 4 mice/group; two-sided and unpaired t-test..  C-E, Western blot (C) of TFEB in 
the cytoplasmic and nuclear fractions of ventricular myocardial proteins and the densitometry data (D, E). 
Here in-lane loading control used the stain-free total protein imaging technology (Supplementary Figure 
4). GAPDH and histone H3 (H3) serve as cytoplasmic and nuclear proteins marks, respectively. N=3 
mice/group; two-sided and unpaired t-test. F and G, Representative images of RT-PCR (F) and 
quantitative real-time PCR (qPCR) data (G) of indicated genes. N=3 mice/group; shown are adjusted p 
value derived from the multiple t-tests corrected with the Holm-Sidak method. Each lane and each dot 
represent a unique mouse.   
 
Figure 4. Genetic PSMI via Psmc1
CKO
 activates myocardial TFEB in mice. A and B, Immunostaining 
of TFEB (green) in the myocardium sections of CTL (yellow circle) and Psmc1CKO (KO; red circle) mice 
at P2. Representative confocal micrographs (A) and the percentage of TFEB-positive nuclei (arrowheads) 
were quantified (B). The sections were counterstained with Phalloidin (red) and DAPI (blue), 
respectively. Bar, 20 µm.  C and D, Western blots (C) and the quantification (D) of TFEB in CTL and 
Psmc1CKO hearts at P2. E, qPCR analyses of indicated genes in CTL and Psmc1CKO hearts. Each lane and 
each dot represent a unique mouse. The p values shown are from two-sided and unpaired t test (B, D), or 
multiple t-tests corrected for multiple testing with the Holm-Sidak method (E).  
 
Figure 5. PSMI by BZM leads to dephosphorylation and nuclear translocation of TFEB in NRVMs. 
NRVMs were treated with BZM (25 nM) or DMSO for 12 or 24 hours before analyses. A, Western blot 
analyses for TFEB (top). The stain-free total proteins (bottom) on the PVDF membrane were used as 
loading control. B and C, NRVMs were treated with DSMO or BZM for 12 hours (B) and 24 hours (C), 
respectively, and subjected to cytosolic and nuclear fractionation, followed by western blot analyses. 
GAPDH and Histone H3 (H3) were probed as a cytoplasmic and nuclear protein marker, respectively. N 
= 3 biological repeats/group. D, NRVMs were treated with DMSO or BZM (25 nM) for 12 hours and 
immunostaind for TFEB (green). The nuclei and F-actin were counterstained with DAPI (blue) and 
Phalloidin (red), respectively. Representative fluorescence confocal micrographs are shown. Scale bar = 
40 μm. E, NRVMs were transfected with siLuci (circle) or siRNA against rat TFEB (siTFEB; triangle) 
for 48 hours, followed by treatment with BZM (25 nM; red) or vehicle (yellow) for additional 24 hours. 




group. P values are derived from two way ANOVA followed by Tukey’s test and are all statistically 
significant after correction for 6 testings (6 genes) with the Benjamini Hochberg procedure.  
 
Figure 6. TFEB activation by PSMI in NRVMs is calcineurin- and Mcoln1-dependent. A and B, 
NRVMs were treated with cyclosporine A (CsA; 1.5 µM; solid circle) or vehicle control (open circle) for 
4 hours and subsequently with BZM (25 nM) for additional 12 hours. Western blot analyses for TFEB in 
the cytosolic and nuclear fractions (A) and the densitometry data (B). GAPDH and histone H3 (H3) were 
probed as a cytoplasmic and nuclear protein marker, respectively. C, Knockdown of calcineurin (Cn) Aβ 
with specific siRNA (siCnAβ) significantly attenuated the activation of TFEB target genes by proteasome 
inhibition with BZM. NRVMs were transfected with siCnAβ (triangle) or siLuci (circle) for 48 hours and 
then treated with bortezomib (BZM, 25 nM; solid symbols) or vehicle control (open symbol) for 
additional 24 hours. The transcripts of the indicated genes were assessed with qPCR. D-F, NRVMs were 
transfected with siRNAs specific for Mcoln1 (si-Mcoln1) or for luciferase (si-Luc) for 72 hours and 
treated with BZM (25 nM) for additional 12 hours. The cells were subjected to subcellular protein 
fractionation or for total RNA extraction. D and E, Western blot analyses for TFEB in the cytosolic and 
nuclear fractions (D) and the densitometry data (E). F, qPCR analyses for the indicated TFEB target 
genes. The p values shown are from two-sided and unpaired t test (B, E) or two way ANOVA followed 
by Tukey’s tests (C, F). All the p values smaller 0.05 in C and F remain statistically significant after 
correction for multiple-testing (6 genes in parallel) using the Benjamini Hochberg procedure. 
 
Figure 7. p62 is required for PSMI to increase autophagic flux in mouse hearts and cardiomyocytes. 
A-C, Western blots (A) and the quantification of myocardial LC3-II (B) and the derived LC3-II flux (C). 
WT and p62KO mice at 6-8 weeks of age were first treated with MG262 (5 µmol/kg, i.p.; solid symbol) 
or vehicle control (DMSO; open symbol) for 11 hours and subsequently with bafilomycin A1 (BFA, 3 
µmol/kg, i.p.; triangle) or DMSO (circle) for additional 1 hour. Ventricular myocardium were collected 
for the analyses. N=3 mice for each group. D-F, LC3-II flux assays for cardiomyocytes isolated from WT 
and p62KO mice at postnatal day 2. The cells were treated with bortezomib (BZM; 25 nM) for 6 hours, 
followed by BFA (25 nM) treatment for additional 6 hours. Shown are western blots (D) of indicated 
proteins and the quantification of LC3-II (E) and derived LC3-II flux (F) from 3 biological repeats. The 
stain-free total proteins serve as loading control (L.C.) and a segment of the image is shown. Data were 
analyzed by two-way (C, F) or three-way (B, E) ANOVA, which all show statistical significance in both 
treatment effects and interaction among factors; as such they were followed by Tukey’s post hoc multiple 




Figure 8. Ablation of p62 (p62KO) attenuates myocardial TFEB activation by PSMI in mice. WT 
and p62KO mice were treated with MG262 or vehicle control as described in Figure 7A. Ventricular 
myocardium was collected for the analyses. A, Confocal micrographs of immunofluorescence staining for 
TFEB (green) and counter-staining with DAPI (blue) for nuclei and with Phalloidin (red) for F-actin. Bar 
= 40 µm. B, qPCR analyses for the indicated target genes of TFEB. Shown p values are derived from two 
way ANOVA followed by Tukey’s test and are all statistically significant after correction for multiple-
testing (5 genes) with the Holm-Sidak method. C, An overall model for proteasome malfunction to 
activate autophagy through the Mcoln1-calcineurin-TFEB-p62 pathway. Proteasome malfunction 
accumulates and activates calcineurin, which in turn dephosphorylates and activates TFEB; the activation 
of TFEB increases the expression of Mcoln1, p62 and other genes of the CLEAR network and thereby 
increases autophagy. Mcoln1 and p62 in turn exert a feed-forward effect on TFEB activation; p62 does so 
potentially through sequestration of mTORC1 into the aggregates of ubiquitinated proteins and thereby 
preventing mTORC1 from phosphorylating TFEB. Meanwhile, p62 recruits and condenses ubiquitinated 
proteins for autophagic degradation. PSMI, proteasome inhibition; CnA, calcineurin; Psmc1KO, 





Novelty and Significance 
 
What is known? 
• Proteasome functional insufficiency contributes to cardiac pathogenesis. 
• Pharmacological proteasome inhibition (PSMI) upregulates calcineurin signaling, p62/Sqstm1, and 
autophagy.   
• Transcription factor EB (TFEB) is a master regulator of the autophagic-lysosomal pathway (ALP). 
 
What new information does this article contribute? 
• Genetic PSMI upregulates p62, activates TFEB, and induces autophagy in cardiomyocytes and 
hearts.  
• Calcineurin and mucolipin 1 (Mcoln1) mediate the TFEB activation by PSMI whereas TFEB in 
turn mediates the upregulation of p62 and autophagy by PSMI in cardiomyocytes.   
• Both p62 and Mcoln1 regulate the TFEB and autophagy activation by PSMI in a feed-forward 
manner.   
Proteasome malfunction is implicated in the progression from a large subset of heart diseases to heart 
failure. Many patients receiving PSMI chemotherapies develop cardiotoxicity. Compensatory activation 
of cardiac autophagy occurs in heart diseases with proteasome malfunction but a mechanistic link 
between proteasome malfunction and autophagy remains obscure. We conducted this study to fill this 
critical gap. Here we have demonstrated that both cardiomyocyte-restricted PSMI and global PSMI 
upregulate myocardial p62 expression, TFEB activity, and autophagy. PSMI induction of TFEB 
dephosphorylation and nuclear translocation, as well as the expression of TFEB target genes (e.g., p62 
and Mcoln1) in cardiomyocytes requires the lysosomal calcium channel Mcoln1 and the activation of the 
calcium-dependent phosphatase calcineurin. p62 deficiency abolishes PSMI induction of myocardial 
autophagy, attenuates the TFEB activation by PSMI, and exacerbates cardiac dysfunction induced by 
PSMI. Thus, we have identified that the Mocln1-calcineurin-TFEB-p62 pathway mediates the autophagy 
activation by the proteasome malfunction in cardiomyocytes and discovered that p62 unexpectedly exerts 
a feed-forward effect on TFEB activation. This not only yields new insight into the cross talk between 
proteasomal and lysosomal degradation but also promotes the search for new therapeutic strategies for 
heart disease with increased proteotoxicity.  
 
